OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.840
+0.030 (1.66%)
Jun 27, 2025, 4:00 PM - Market closed
OS Therapies Employees
As of December 31, 2024, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,654,556
Market Cap
51.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OSTX News
- 4 days ago - OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma - Business Wire
- 4 days ago - OS Therapies Announces Warrant Exercise Inducement & Exchange Offer - Business Wire
- 18 days ago - OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma - PRNewsWire
- 22 days ago - OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma - Business Wire
- 6 weeks ago - OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma - Business Wire
- 7 weeks ago - OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040 - Business Wire
- 2 months ago - Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies - Business Wire